Stockysis — AI-Powered Stock News & Sentiment Analysis

Piper Sandler Reiterates Overweight on Capricor Therapeutics, Raises Price Target to $58

Benzinga Newsdesk www.benzinga.com Positive 67.8%

Neg 0% Neu 0% Pos 67.8%

Piper Sandler analyst Edward Tenthoff reiterates Capricor Therapeutics (NASDAQ:CAPR) with a Overweight and raises the price target from $45 to $58.

Comments

No comments yet. Be the first!